Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar-Apr;2(2):148-56.
doi: 10.4161/mabs.2.2.11159.

Antibody immunosuppressive therapy in solid-organ transplant: Part I

Nadim Mahmud  1 , Dusko Klipa, Nasimul Ahsan
Affiliations
Review

Antibody immunosuppressive therapy in solid-organ transplant: Part I

Nadim Mahmud et al. MAbs. 2010 Mar-Apr.

Abstract

Currently, a wide variety of both polyclonal and monoclonal antibodies are being routinely utilized to prevent and treat solid organ rejection. More commonly, these agents are also administered in order to delay introduction of calcineurin inhibitors, especially in patients with already compromised renal function. While these antibody therapies dramatically reduced the incidence of acute rejection episodes and improved both short and long-term graft survival, they are also associated with an increased incidence of opportunistic infections and neoplastic complications. Therefore, effective patient management must necessarily balance these risks against the potential benefits of the therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The anti-alograft response.
Figure 2
Figure 2
Trends of use of polyclonal antibodies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963;268:1315–1323. - PubMed
    1. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet. 1979;8151:1033–1036. - PubMed
    1. Norman D, Turka L. Primer on Transplantation. Wiley Blackwell; 2001.
    1. Collins WA, Humphreys RM, Davis MB, Ibele WE, Dworkin M, Kinsey J, et al. The Crime of Saving Lives: The FDA, John Najarian and Minnesota ALG. Arch Surg. 1996;131:451–452. - PubMed
    1. Wechter WJ, Brodie JA, Morrell RM, Rafi M, Schultz JR. Antithymocyte Globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen. Transplantation. 1979;28:294–302. - PubMed

MeSH terms

Substances